ABIONYX Pharma has completed a €18.7 million capital increase, with the rights issue subscribed at 100% and resulting in the issuance of 7,056,416 new shares. Settlement and delivery of the shares are scheduled for June 22, 2026.
The Toulouse-based biopharmaceutical company is developing therapies for sepsis and critical care based on its apoA-I technology platform. ABIONYX said the proceeds will help fund its Phase 2b clinical trial in sepsis, support work toward a Marketing Authorization Application with the EMA for its LCAT Deficiency program, and cover general corporate purposes, working capital needs, and possible bond-related debt repayment.
The transaction also brings Denmark-based Fenja Capital II A/S into the shareholder structure with 1,002,579 shares following the financing. The raise gives ABIONYX additional funding as it advances two key programs in sepsis and rare disease.
The Toulouse-based biopharmaceutical company is developing therapies for sepsis and critical care based on its apoA-I technology platform. ABIONYX said the proceeds will help fund its Phase 2b clinical trial in sepsis, support work toward a Marketing Authorization Application with the EMA for its LCAT Deficiency program, and cover general corporate purposes, working capital needs, and possible bond-related debt repayment.
The transaction also brings Denmark-based Fenja Capital II A/S into the shareholder structure with 1,002,579 shares following the financing. The raise gives ABIONYX additional funding as it advances two key programs in sepsis and rare disease.